Eutropics is a pioneering brand in the field of personalized medicine, offering an innovative biomarker technology platform called PraediCare Dx™. This platform holds immense potential for accelerating drug discovery and development. With a focus on predicting treatment response, Eutropics' PraediCare Dx™ provides novel and highly accurate diagnostic tests that are tailored to guide patient cancer treatments.

Eutropics has successfully demonstrated the medical utility of their predictive tests in blood cancers, with specific validatations for Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia. With a CLIA certification, the company is equipped to handle clinical samples from most U. S.

Based in Cambridge, Massachusetts, Eutropics Pharmaceuticals is committed to advancing personalized medicine and delivering innovative solutions for patients and healthcare providers alike. Their dedicated team of experts, along with strategic partnerships and a strong industry presence, solidify Eutropics as a leading brand in the field. Contact Eutropics today to learn more about their cutting-edge biomarker technology and revolutionize the path of treatment for individual cancer patients